<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the prevalence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) together with immunological characteristics of patients with occlusive <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disorders</z:e> (ORVD) with and without risk factors (systemic arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo>, and embolizing <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e>) for <z:chebi fb="46" ids="15035">retinal</z:chebi> occlusions compared to patients with ocular <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OID</z:e>) and healthy controls </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Sixty-eight patients with ORVD, 45 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OID</z:e>, and 49 healthy persons were prospectively studied </plain></SENT>
<SENT sid="2" pm="."><plain>Serologic studies included determination of anticardiolipin antibodies, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, <z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo> (ANA), levels of complement 4 and 3, total hemolytic complement (CH100), and circulating immune complexes (CIC) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Elevated levels of aPL were detected in 16 (24%) patients with ORVD compared to 4 (9%) patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OID</z:e> (OR 3.15, p &lt; 0.05) and 4 (8%) controls (OR 3.46, p &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>No significant differences were seen in the prevalence of aPL comparing risk factor-positive patients with ORVD (8 of 33, 24%) to risk factor-free patients with ORVD (8 of 35, 23%) </plain></SENT>
<SENT sid="5" pm="."><plain>A higher frequency of positive ANA, <z:hpo ids='HP_0003261'>elevated IgA</z:hpo>, and increased CIC were detected in aPL positive patients with ORVD compared to patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OID</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Detection of aPL in patients with ORVD may help determine which patients are eligible for prophylactic treatment </plain></SENT>
<SENT sid="7" pm="."><plain>An immunologic profile characterized by high prevalence of ANA, CIC, and <z:hpo ids='HP_0003261'>elevated IgA</z:hpo> distinguishes ORVD patients with aPL from inflammatory ophthalmologic disorders </plain></SENT>
</text></document>